FDA approves Allergan’s sNDA for BOTOX for pediatric upper limb spasticity

The FDA has approved Allergan’s (NYSE:AGN) supplemental biologics application (sBLA) for BOTOX for the treatment of pediatric patients (2 to 17 years of age) with upper limb spasticity.

The FDA is also reviewing an additional sBLA for the use of BOTOX to treat pediatric patients with lower limb spasticity, with a decision expected in Q4.

https://seekingalpha.com/news/3472924-fda-approves-allergans-snda-botox-pediatric-patients-upper-limb-spasticity